Antibodies With Modified Affinity To Fcrn That Promote Antigen Clearance
Patent No. EP3181581 (titled "Antibodies With Modified Affinity To Fcrn That Promote Antigen Clearance") was filed by Chugai Seiyaku Kabushiki Kaisha on Mar 30, 2011. The application was issued on Sep 25, 2024.
Patent Summary
Antigen-binding molecules, such as antibodies, that facilitate antigen uptake into cells by leveraging human FcRn binding activity in acidic pH environments. The molecules exhibit enhanced FcRn binding in neutral pH conditions and reduced antigen binding affinity in acidic pH conditions, enabling efficient antigen internalization and recycling. This property enables the molecules to repeatedly bind and eliminate multiple antigens, reducing plasma antigen concentrations and enhancing pharmacokinetics. The molecules can be engineered through targeted amino acid substitutions in the FcRn binding domain or antigen binding domain to optimize their properties.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3181581
- Application Number
- EP17154576A
- Filing Date
- Mar 30, 2011
- Status
- Granted And Under Opposition
- Aug 22, 2024
- Publication Date
- Sep 25, 2024
- External Links
- Slate, Register , Google Patents